Consumer Brands & Retail
GLP-1 Didn't Just Change Bodies. It Changed the Prompts.
Eight verticals are rewriting their language for ChatGPT, Claude, Gemini, and Perplexity, because the buyer now asks the bot before the shelf every time.
Tag
Ozempic — Tagged Articles
Healthcare
OZEMPIC OWNS THE CHATBOX
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Healthcare
Novo Nordisk vs Eli Lilly: Who Owns the GLP-1 Answer
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
Consumer Brands & Retail
How Wellness Brands Win AI Search
The wellness industry outgrew the media infrastructure that once covered it. AI engines now fill the trust vacuum. Everything-PR's complete cluster on wellness communications and AI visibility in a $1.8 trillion category.
Consumer Brands & Retail
Ozempic Rewrote the Wellness Industry
Novo Nordisk's Ozempic threatened $1.8T wellness. GLP-1s reset the consumer contract. Levels and Function survived. Weight-loss supplement SKUs got pulled.
Marketing
Weight Loss Marketing in the GLP-1 Era: The 2026 Reference
The U.S. weight-loss category was rewritten by GLP-1s. Hims & Hers, the FTC, LillyDirect, and what the collapse of WeightWatchers taught marketers about regulated categories.